A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies.
Latest Information Update: 06 May 2022
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 02 Jun 2010 Merck added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.
- 01 Oct 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 30 Jan 2008 The expected completion date for this trial is now 1 Dec 2008.